LTR PHARMA LTD(LTP.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

LTP.AU LTR PHARMA LTD

Trading 11-15 10:07:35 AEDT

1.34

-0.02

-1.47%

High1.36	Low1.34	Vol31.23K
Open1.36	D1 Closing1.36	Amplitude1.47%
Mkt Cap206.10M	Tradable Cap100.04M	Total Shares153.80M
T/O42.28K	T/O Rate0.04%	Tradable Shares74.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LTP.AU","market":"AU","secType":"STK","nameCN":"LTR PHARMA LTD","latestPrice":1.34,"timestamp":1731625624526,"preClose":1.36,"halted":0,"volume":31234,"delay":0,"nameEN":"LTR PHARMA LTD","floatShares":74654833,"shares":153803814,"eps":-0.0499,"marketStatus":"Trading","change":-0.02,"latestTime":"11-15 10:07:35 AEDT","open":1.36,"high":1.36,"low":1.34,"amount":42275,"amplitude":0.014706,"askPrice":1.355,"askSize":1975,"bidPrice":1.325,"bidSize":1614,"shortable":3,"etf":0,"ttmEps":-0.0499,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1731646800000},"marketStatusCode":2,"adr":0,"listingDate":1702126800000,"exchange":"ASX","adjPreClose":1.36,"openAndCloseTimeList":[[1731625200000,1731646800000]],"volumeRatio":1.298078,"lotSize":0,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/LTP.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2482471940","title":"LTR Pharma Joins Forces to Launch Men's Health Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2482471940","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482471940?lang=en_us&edition=fundamental","pubTime":"2024-11-12 11:15","pubTimestamp":1731381329,"startTime":"0","endTime":"0","summary":"LTR Pharma  partnered with the Restorative Sexual Health Clinic to establish an online men's health platform, according to a Tuesday filing with the Australian bourse.The platform is set to launch in the first quarter of 2025, offering medical consultations, therapeutic services, and prescription treatments for Australian men, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","XAO.AU","XKO.AU","LTP.AU","BK7096"],"gpt_icon":0},{"id":"2482945727","title":"BUZZ-Australia's LTR Pharma jumps on JV for online health platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2482945727","media":"reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482945727?lang=en_us&edition=fundamental","pubTime":"2024-11-12 09:19","pubTimestamp":1731374383,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's LTR Pharma jumps on JV for online health platform** Shares of LTR Pharma LTP.AX rise as much as 6.2% to A$1.63, hitting their highest since Oct. 22** Stock logs its fifth consecutive session of gains** Biotech co signs joint venture agreement with local men's health group Restorative Sexual Health Clinic** JV to launch an online healthcare platform for medical consultations, therapeutic services and prescription treatments** Online platform expected to launch in the first quarter of 2025** LTP up 355.1% YTD, including current session's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL4N3MJ024:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTP.AU","BK7096"],"gpt_icon":0},{"id":"2482645987","title":"ASX Market Open: Australian market set to open slightly lower following a mixed session on Wall Street | November 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2482645987","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482645987?lang=en_us&edition=fundamental","pubTime":"2024-11-12 06:07","pubTimestamp":1731362820,"startTime":"0","endTime":"0","summary":"The ASX200 is set to open 0.15% lower today, following mixed performances among US bourses on Monday.This was led by a 304-point rally on the Dow, which saw it end the session at 44,293 for the first time, extending the rally it has enjoyed since the US election – itself built around the expectation that Donald Trump’s return to the White House will translate into deregulation and tax cuts. By contrast, the S&P 500 was only slightly higher at the end of the session, and the Nasdaq was flat in the wake of tech stock losses, including Apple , Nvidia , and Meta .On the ASX, Sunstone Metals Ltd  has discovered a new copper-gold porphyry at its Bramaderos project in Ecuador, and LTR Pharma Ltd  has announced a strategic joint venture with leading men’s health group the Restorative Sexual Health Clinic, to develop an online platform.Join the discussion: See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-open-australian-market-set-to-open-slightly-lower-following-a-mixed-session-on-wall-street-november-12-2024-2024-11-12/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7096","STM.AU","XJO.AU","BK7095","XKO.AU","XAO.AU","LTP.AU"],"gpt_icon":0},{"id":"2475375253","title":"LTR Pharma Says Study Found SPONTAN Nasal Spray Had 470% Faster Absorption Than Oral Tablet","url":"https://stock-news.laohu8.com/highlight/detail?id=2475375253","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475375253?lang=en_us&edition=fundamental","pubTime":"2024-10-15 10:15","pubTimestamp":1728958515,"startTime":"0","endTime":"0","summary":"LTR Pharma  completed the data evaluation phase of its clinical study on SPONTAN, its intranasal formulation of erectile dysfunction medication vardenafil, according to a Monday filing with the Australian Securities Exchange.The study found that SPONTAN nasal spray had a 470% faster absorption rate than oral tablets and was well-tolerated with no serious adverse events, the filing said.LTR Pharma shares were down nearly 2% in midday trade Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTP.AU","BK7096"],"gpt_icon":0},{"id":"2475800877","title":"ASX Market Update: Index nears record territory as miners surge | October 14, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475800877","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475800877?lang=en_us&edition=fundamental","pubTime":"2024-10-14 11:05","pubTimestamp":1728875100,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.26% at 8,236 points.The gains have been less than expected amid investor caution about a potential negative reaction by China’s markets to vague stimulus announcements on the weekend.Back home, CBA’s head of Australian economics says several surveys indicate the disinflationary process has gathered momentum in the September quarter. However, the Q3 CPI data on October 30 is regarded as the strongest inflation indicator.Sectors are a mixed bag. Materials are leading strongly, up 2.25%, followed by Health Care, up 0.64% and Financials up 0.34%.Discretionary is the worst performer, down 1%, followed by IT, down 0.7% and Utilities, 0.4%.Power and communications infrastructure provider GenusPlus  has been up nearly 2% on news its buying Partum Engineering. The binding conditional deal is worth $16 million.Lincoln Minerals is set to kick off fieldwork sampling exploration work at its Yallunda uranium play in South Australia.Lincoln Minerals has been trading at six te","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-index-nears-record-territory-as-miners-surge-october-14-2024-2024-10-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7095","XAO.AU","LML.AU","BK7096","GNP.AU","LTP.AU","BK7055","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2475879754","title":"LTR Pharma’s SPONTAN ‘nasal viagra’ absorbed 470% times faster than oral solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2475879754","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475879754?lang=en_us&edition=fundamental","pubTime":"2024-10-14 06:28","pubTimestamp":1728858480,"startTime":"0","endTime":"0","summary":"LTR Pharma  has posted final study results showing its ‘nasal viagra’ drug SPONTAN is absorbed 470% faster than oral tablets.The data ultimately underscores that value proposition very serious investment analysts on George St have been eyeing – a superior product that can produce erections in far faster timeframes.While the subject matter may be joke-inducing, the value proposition is real. A lot can happen in the forty minutes it takes for better known oral solutions to work.LTR Pharma also reported on Monday the product – and this is by way of it being sprayed directly up the nose – has a greater bioavailability than oral tablets. . The drug was well tolerated with no adverse effects reported. The company says its drug is overall as safe as oral tablets.“The rapid onset of action and pharmacokinetic profile of SPONTAN have the potential to address significant unmet needs in erectile dysfunction treatment” LTP CMO Prof. Geoffrey Strange said.Join the discussion: See what HotCopper use","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/ltr-pharmas-spontan-nasal-viagra-absorbed-470-times-faster-than-oral-solution-2024-10-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LTP.AU","BK7096"],"gpt_icon":0},{"id":"2472665825","title":"Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger","url":"https://stock-news.laohu8.com/highlight/detail?id=2472665825","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472665825?lang=en_us&edition=fundamental","pubTime":"2024-10-02 05:15","pubTimestamp":1727817300,"startTime":"0","endTime":"0","summary":"For those not regular watchers of the ASX biotech sector, it’s worth noting Recce Pharmaceuticals  has been on a tear this year.Recce is developing its flagship patented next-gen anti-infective, R327, with clinical results so far across Diabetic Foot Infection  and Acute Bacterial Skin and Skin Structure Infection ; and, Urosepsis/Urinary Tract Infection  trials, pointing towards a potential commercial value proposition.At the time of writing – 1.30PM in afternoon trades on Tuesday 1 October 2024 – Recce’s one-year returns are up over +16%.We’ve seen a number of other biotech companies hit the bourse in recent history with investor interest in the sector.LTR Pharma , developing a nasal spray Viagra competitor, has posted gains of +444% YTD; while Cleo Diagnostics , developing a blood test for early detection of ovarian cancer, is up +128% YTD.Recce Pharma, for its part, has been on the bourse for closer to a decade now, after a 20c IPO raise and opening at about 40cps back in January 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/recce-eyes-indonesia-for-novel-anti-infective-as-indo-aus-ties-grow-stronger-2024-10-02/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LTP.AU","BK7096","XAO.AU","BK4588","UTI","BK4204","RCE.AU","XKO.AU","XJO.AU","COV.AU","BK4006","AMR","BK4585"],"gpt_icon":0},{"id":"2472581393","title":"'Exciting prospect': 2 ASX pharmaceutical shares to keep a close eye on","url":"https://stock-news.laohu8.com/highlight/detail?id=2472581393","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472581393?lang=en_us&edition=fundamental","pubTime":"2024-10-01 09:29","pubTimestamp":1727746156,"startTime":"0","endTime":"0","summary":"ASX pharmaceutical shares and other healthcare stocks are off to a positive start on Tuesday.  The S&P/ASX 200 Health Care Index (ASX: XHJ) is up 0.46%, while the benchmark ASX 200 is down 0.39%. At t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/01/exciting-prospect-2-asx-pharmaceutical-shares-to-keep-a-close-eye-on/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4213","BK7001","LTP.AU","BK7067","TGA","TGA.AU","BK4139","BK7508","BK7095","OPT.AU","OPT","BK7096","DME.AU"],"gpt_icon":0},{"id":"2466440958","title":"5 pharma & biotech stocks on the move in August","url":"https://stock-news.laohu8.com/highlight/detail?id=2466440958","media":"LiveWire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466440958?lang=en_us&edition=fundamental","pubTime":"2024-09-11 11:31","pubTimestamp":1726025463,"startTime":"0","endTime":"0","summary":"The market was up slightly in August with the ASX All Ordinaries Accumulation Index up 0.4%, however the story was mixed between sectors. Energy was the worst performing sector with the ASX 300 Energy Accumulation Index down 6.2% for the month, while Financials was the best performer with the ASX 300 Financial Accumulation Index up 7.2% largely driven by the banks. The ASX 300 Health Care Accumulation Index was down 0.9% with the largest stock in the index, CSL, falling 0.8%.For the Pharma & Biotech coverage universe, there were some significant gainers with 11 stocks in the universe increasing by more than 30% in August and 57 of the 149 stocks delivering a positive share price performance. Below we take a look at 5 Pharma & Biotech companies whose share prices rallied in August.Phosphodiesterase type 5 inhibitors  are the most commonly prescribed first-line treatment for ED, however there is a high percentage of patients who are unresponsive and drop out of treatments. In a recent in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/5-pharma-biotech-stocks-on-the-move-in-august-2024-09-11","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/5-pharma-biotech-stocks-on-the-move-in-august-2024-09-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU0109392836.USD","LU0198837287.USD","PYC.AU","BK4573","LTP.AU","LU0823434740.USD","BK7094","LU1923623000.USD","LU1852331112.SGD","BK4554","BK4588","BK4097","ARR","IE00BMPRXR70.SGD","LU1880398471.USD","IE00B5949003.HKD","LU2250418816.HKD","BK4529","BK7508","BK4139","EZZ.AU","IE00BMPRXN33.USD","LU0823421333.USD","LU0823434583.USD","BK4575","BK7067","LU2346227817.USD","BMT.AU","BK4208","LU1303367103.USD","OPT","LU0889565833.HKD","RPD","LU0719512351.SGD","ED","LU1878469433.USD","LU1989764664.SGD","BK4532","OPT.AU","BK4110","BK4585","LU1242518857.USD","BK7096","LU1880398554.USD","LU2264538146.SGD","MAD.AU","LU0082616367.USD","LU0127658192.USD","ARR.AU"],"gpt_icon":1},{"id":"2464862996","title":"LTR Pharma Limited's (ASX:LTP) biggest owners are private companies who got richer after stock soared 14% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2464862996","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464862996?lang=en_us&edition=fundamental","pubTime":"2024-09-03 05:20","pubTimestamp":1725312037,"startTime":"0","endTime":"0","summary":"Significant control over LTR Pharma by private companies implies that the general public has more power to influence management and governance-related decisions. 51% of the business is held by the top 9 shareholders. Using data from company's past performance alongside ownership research, one can better assess the future performance of a company. A look at the shareholders of LTR Pharma Limited  can tell us which group is most powerful. And the group that holds the biggest piece of the pie are private companies with 45% ownership. In other words, the group stands to gain the most  from their investment into the company.Clearly, private companies benefitted the most after the company's market cap rose by AU$60m last week.Let's delve deeper into each type of owner of LTR Pharma, beginning with the chart below.I generally consider insider ownership to be a good thing. Howe","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ltr-pharma-limiteds-asx-ltp-212037323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2459686231","title":"LTR Pharma Prescribes Erectile Dysfunction Medication Under Special Access Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2459686231","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459686231?lang=en_us&edition=fundamental","pubTime":"2024-08-16 09:52","pubTimestamp":1723773145,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK7001","TGA.AU","XAO.AU","TGA","XKO.AU","BK7096","BK4213","XJO.AU","LTP.AU"],"gpt_icon":0},{"id":"2459316342","title":"LTR Pharma Prescribes Erectile Dysfunction Medication Under Special Access Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2459316342","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459316342?lang=en_us&edition=fundamental","pubTime":"2024-08-16 09:52","pubTimestamp":1723773145,"startTime":"0","endTime":"0","summary":"LTR Pharma  prescribed its erectile dysfunction medication Spontan to a first batch of patients under the Australian Therapeutic Goods Administration's  Authorized Prescriber Scheme, according to a Friday filing with the Australian Securities Exchange.The scheme will allow specialists to prescribe the nasal spray medication to patients with unmet needs, the pharmaceutical firm said in the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TGA.AU","XJO.AU","BK7001","BK4213","BK7096","TGA","LTP.AU","XAO.AU","XKO.AU"],"gpt_icon":0},{"id":"2459691146","title":"Why is this ASX small cap ripping 37% ahead on Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2459691146","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459691146?lang=en_us&edition=fundamental","pubTime":"2024-08-13 12:23","pubTimestamp":1723522983,"startTime":"0","endTime":"0","summary":"LTR Pharma Ltd  shares are on fire on Tuesday afternoon. At the time of writing, the ASX small cap share is up 37% to a record high of $1.32. Why is this ASX small cap rocketing?Investors have been fighting to get hold of the pharmaceutical company's shares this morning following the release of a promising announcement. According to the release, the company has entered into a co-development agreement for its Sponton product for global markets. The agreement has been secured with Aptar Pharma , which is a global leader in drug delivery systems, services, and active material science solutions. The ASX small cap notes that Aptar Pharma has supported numerous market authorisation holders in obtaining their combination drug-device product approvals incorporating Aptar's nasal delivery systems. This includes from regulatory agencies such as the U.S. Food and Drug Administration . What is the agreement?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/08/13/why-is-this-asx-small-cap-ripping-37-ahead-on-tuesday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7001","TGA.AU","BK7096","LTP.AU","BK4126","BK4213","TGA","ATR"],"gpt_icon":0},{"id":"2459918497","title":"LTR Pharma, Aptar Pharma Enter Co-Development Agreement for SPONTAN Nasal Spray; LTR Shares Jump 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459918497","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459918497?lang=en_us&edition=fundamental","pubTime":"2024-08-13 11:01","pubTimestamp":1723518072,"startTime":"0","endTime":"0","summary":"Pharmaceutical company LTR Pharma  and drug delivery firm Aptar Pharma entered into a co-development agreement for SPONTAN nasal spray for global markets, according to a Tuesday filing with the Australian bourse.The main goal of the agreement is to commercialize SPONTAN in the US and other major markets. The nasal spray is designed to treat erectile dysfunction faster than tablets, the filing said.Shares of LTR Pharma jumped over 18% in recent trade.Price : $1.14, Change: $+0.18, Percent Change: +18.13%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK4125","LTP.AU","AUD"],"gpt_icon":0},{"id":"2459913390","title":"LTR Pharma, Aptar Pharma Enter Co-Development Agreement for SPONTAN Nasal Spray; LTR Shares Jump 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459913390","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459913390?lang=en_us&edition=fundamental","pubTime":"2024-08-13 11:01","pubTimestamp":1723518072,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4125","BK7096","AUD","XJO.AU","XKO.AU","XAO.AU","LTP.AU"],"gpt_icon":0},{"id":"2459891856","title":"BUZZ-Australia's LTR Pharma hits record high on partnership for nasal spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2459891856","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459891856?lang=en_us&edition=fundamental","pubTime":"2024-08-13 10:56","pubTimestamp":1723517799,"startTime":"0","endTime":"0","summary":"** Shares of LTR Pharma    soar as much as 29.5% to a record high of A$1.250   ** Biopharmaceutical co signs co-development agreement with Aptar Pharma for SPONTAN nasal spray for global markets   ** Primary goal is commercialisation of SPONTAN in the United States and other key markets - co   ** Says partnership with Aptar Pharma will be beneficial in obtaining U.S. Food and Drug Administration  approval for SPONTAN   ** Stock posts its biggest intraday pct gain since June 7   ** About 2.3 mln shares change hands, compared with the 30-day average volume of 600,999   ** Stock up 179.7% this year, as of last close ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XJO.AU","BK7096","LTP.AU","XAO.AU","XKO.AU"],"gpt_icon":0},{"id":"2459424849","title":"Stocks of the Hour: Terrain Minerals, Leeuwin Metals, LTR Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2459424849","media":"Informed Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459424849?lang=en_us&edition=fundamental","pubTime":"2024-08-13 09:30","pubTimestamp":1723512644,"startTime":"0","endTime":"0","summary":"A snapshot of the stocks on the move, featuring Terrain Minerals (ASX:TMX), Leeuwin Metals (ASX:LM1) and LTR Pharma (ASX:LTP).","market":null,"thumbnail":"https://informed-investor.s3.ap-southeast-2.amazonaws.com/images/News/ed072118a25536c5fd791dea5973afdd401c6977.jpg","type":0,"news_type":0,"thumbnails":["https://informed-investor.s3.ap-southeast-2.amazonaws.com/images/News/ed072118a25536c5fd791dea5973afdd401c6977.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finnewsnetwork.com.au/archives/finance_news_network470605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7104","LM1.AU","LTP.AU","BK7095","BK7096","TMX.AU"],"gpt_icon":0},{"id":"2459833996","title":"BRIEF-LTR Pharma Secures Global Co-Development Agreement With Aptar Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2459833996","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459833996?lang=en_us&edition=fundamental","pubTime":"2024-08-13 09:21","pubTimestamp":1723512107,"startTime":"0","endTime":"0","summary":"Aug 13 (Reuters) - LTR Pharma Ltd   :   * SECURES GLOBAL CO-DEVELOPMENT AGREEMENT WITH APTAR PHARMA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","LTP.AU"],"gpt_icon":0},{"id":"2459140149","title":"LTR Pharma partners with Aptar to advance SPONTAN ED nasal spray in key global markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2459140149","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459140149?lang=en_us&edition=fundamental","pubTime":"2024-08-13 09:06","pubTimestamp":1723511193,"startTime":"0","endTime":"0","summary":"LTR Pharma  and US-based Aptar Pharma have entered into a co-development agreement to commercialise LTR’s SPONTAN erectile dysfunction nasal spray in the US and other key markets.The agreement will combine LTR’s pharmaceutical development capabilities with Aptar’s expertise in nasal spray technology to support a streamlined regulatory pathway and market access for the product.It gives LTR access to Aptar’s comprehensive range of regulatory, analytical testing and human factors services to strengthen the application process for SPONTAN with the US Food and Drug Administration .LTR chair Lee Rodne said the companies would focus on imminent market establishment and expansion and form a long-term strategic alliance for ongoing innovations in healthcare solutions.“We are delighted to enter into this agreement with a respected and experienced partner such as Aptar Pharma, with the goal of obtaining regulatory approval for SPONTAN and expanding our global market reach and impact,” he said.In ","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/08/LTR-Pharma-ASX-LTP-Spontan-Aptar-agreement.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/08/LTR-Pharma-ASX-LTP-Spontan-Aptar-agreement.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://smallcaps.com.au/ltr-pharma-partners-aptar-advance-spontan-ed-nasal-spray-key-global-markets/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK4585","BK4208","ED","BK7096","LU0170899867.USD","LTP.AU","BK4588"],"gpt_icon":0},{"id":"2459961783","title":"LTR Pharma Ltd - Secures Global Co-Development Agreement With Aptar Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2459961783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459961783?lang=en_us&edition=fundamental","pubTime":"2024-08-13 07:17","pubTimestamp":1723504643,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240812:nFWN3JZ1XX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LTP.AU","BK7096"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ltrpharma.com","stockEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":-0.2444},{"period":"3month","weight":0.0794},{"period":"6month","weight":2.831},{"period":"1year","weight":5.8},{"period":"ytd","weight":2.942}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0252},{"period":"3month","weight":-0.022},{"period":"6month","weight":-0.0006},{"period":"1year","weight":0.1369},{"period":"ytd","weight":0.1205}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"exchange":"ASX","name":"LTR PHARMA LTD","nameEN":"LTR PHARMA LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LTR PHARMA LTD(LTP.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LTR PHARMA LTD(LTP.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LTR PHARMA LTD,LTP.AU,LTR PHARMA LTD股票,LTR PHARMA LTD股票老虎,LTR PHARMA LTD股票老虎国际,LTR PHARMA LTD行情,LTR PHARMA LTD股票行情,LTR PHARMA LTD股价,LTR PHARMA LTD股市,LTR PHARMA LTD股票价格,LTR PHARMA LTD股票交易,LTR PHARMA LTD股票购买,LTR PHARMA LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LTR PHARMA LTD(LTP.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LTR PHARMA LTD(LTP.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction